Search results for Astrazeneca

CDT Equity Advances AstraZeneca PLC (AZN)’s AZD5904 Into PCT Patent Protection Stage

AstraZeneca’s $800M bet undermined by immunogenicity in phase 3

Immunogenicity dragged on the efficacy of AstraZeneca’s rare endocrine disorder prospect in a phase 3 trial, causing the $800 million molecule’s response rate to fall short of the...

AstraZeneca wins go-ahead for Cambridge conference centre

Pharma giant secures approval for six-storey campus hub

AstraZeneca India plans to sell 64-acre Bengaluru site for ₹3,400 crore

AstraZeneca's Indian unit is planning to sell its 64-acre manufacturing facility in North Bengaluru for an estimated ₹3,400 crore. The move is part of a global review of its manufa...

AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins

AstraZeneca pens agentic AI licensing deal with Owkin

AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year licensing deal with Owkin to leverage its autonomous “AI...

<![CDATA[Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra]]>

FDA approves AstraZeneca’s new kind of hypertension drug

Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in an...

AstraZeneca restarts £300M investment in UK, but Merck not budging

AstraZeneca has announced it will resume a £300 million investment program in the U.K., seven months after freezing the plans in frustration at national government drug pricing neg...

Astra invests £300m in Britain after government agrees to spend more on medicines

It marks a partial U-turn after the drugs giant, Britain's biggest listed company, put a plan to spend £200m on its Cambridge site on pause last year.

What next for AstraZeneca shares, after another cracking quarter?

AstraZeneca shares have made storming gains since Pascal Soriot became the boss. The latest outlook suggests it could be far from over. The post What next for AstraZeneca shares, a...

AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval

AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the rare disease drug candidate to a 62% improvement in survival in a prespecified su...

AstraZeneca Imfinzi combo improves survival in bladder cancer study

AstraZeneca makes surprise U-turn with £300m pharma investment in UK

Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir StarmerBritain’s biggest drugmaker AstraZeneca has said it will...

<![CDATA[First Patient Dosed with Azenosertib in Aspenova Phase III Trial for Treatment of Ovarian Cancer]]>

FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure

AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and...

AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win, offering further evidence the Big Pharma may have cracked the anti-IL-33 cod...

AstraZeneca: The Bigger Picture Remains Solid Growth Amidst Improving Margins And Returns

AstraZeneca plucks preclinical EGFR degrader from Pinetree for $25M

AstraZeneca has paid $25 million to pick up a preclinical EGFR degrader that was at the center of its existing pact with Pinetree Therapeutics.

Hopes raised for next phase of AstraZeneca development in Cambridge after drugmaker commits to £300m spend in UK

Firm reverses decision last year to halt spending because of concerns over drug pricing

Next phase of AstraZeneca campus development in Cambridge approved

Six-storey office and conference centre scheme to be located close to pharma giant’s HQ completed by Mace five years ago

Cancer drug demand helps AstraZeneca and GSK boost their bottom lines

Pharmaceutical drug giants AstraZeneca and GSK both saw cancer drug sales rise in their latest quarter.

AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestrant in a novel first-line switch setting in HR-positive, HER2-negative m...

Building Trust-Driven Partnerships: AstraZeneca’s Concierge Approach to Accelerating Site Activation and Enrollment

AstraZeneca’s approach to collaboration has enabled faster site activation, stronger recruitment performance, and improved data delivery.